Pharmadrug Inc.
LMLLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -30.7% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $0 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $3 |
| Operating Income | -$1 | -$1 | -$2 | -$3 |
| % Margin | – | – | – | -38,578.1% |
| Other Income/Exp. Net | -$0 | -$13 | -$1 | -$2 |
| Pre-Tax Income | -$1 | -$14 | -$3 | -$4 |
| Tax Expense | $0 | -$1 | -$0 | $0 |
| Net Income | -$1 | -$13 | -$9 | -$6 |
| % Margin | – | – | – | -83,806.5% |
| EPS | -0.008 | -0.23 | -0.061 | -0.12 |
| % Growth | 96.7% | -275.8% | 49% | – |
| EPS Diluted | -0.008 | -0.23 | -0.061 | -0.12 |
| Weighted Avg Shares Out | 99 | 56 | 50 | 48 |
| Weighted Avg Shares Out Dil | 104 | 56 | 50 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$2 | -$4 |
| % Margin | – | – | – | -60,037.1% |